Introduction
Bartter syndrome (BS) and Gitelman syndrome (GS) are rare autosomal recessive (AR) syndromes (1,2). These two syndromes are characterized with hypokalemia, metabolic alkalosis, hyperreninemia, hyperplasia in the juxtaglomerular apparatus and secondary hyperaldosteronism (3, 4, 5, 6) . Bartter syndrome is often diagnosed before 6 years of life with clinical signs including polyuria, polydipsia, vomiting, constipation, salt cravings, growth retardation and fatigue. Some patients present growth and developmental delay (4-7-8-9) . Whereas GS is usually diagnosed in the infancy period with similar symptoms, although it may diagnosed in late childhood, even in adulthood period depending on the type of genetic mutation (12). In extremely rare cases, GS may diagnose with growth retardation in an early age (10) . Both diseases are characterized with hypopotassemia. In this 3-case series, growth retardation was identified at 17-year follow-up of our dizygotic twin patients diagnosed with BS and glucose metabolism disorder was developed. Whereas, our other patient diagnosed with GS in adulthood period developed diabetes mellitus (DM). Herein, we aimed to draw attention to that, the presence of chronic hypopotassemia may precipitate to diseases such as growth retardation and diabetes mellitus over time
Cases Case 1:
First of the twins was examined due to vomiting, polyuria, polydipsia, dehydration, weight loss and growth retardation beginning from the birth. Height and weight of the patient were below the 3rd percentile. Laboratory tests revealed potassium (K): 2.04 mmol/L, sodium (Na): 142 mmol/l, calcium (Ca): 8.8 mg/dl, magnesium (Mg): 1.56 mg/dl and chlorine (Cl): 95 mmol/l. In the venous blood gas, pH was 7.60, HCO3: 38.9 mmol/l and pCO2: 30.2 mmHg (32-48). Upon the patient was diagnosed with hypokalemic, hypochloremic metabolic alkalosis, additional studies were carried out. Aldesterone was found as 1933.2 pg/ml (35-410) and Angiotensin-1 as 19 ng/ml (1.5-5.5). Since the patient who was diagnosed with Bartter syndrome when he was 11-month-old developed growth and developmental retardation from the birth, IGF-1 was examined and found as 38.3 ng/mL (288-736). He had no familial history of growth retardation. The patient who was diagnosed with growth retardation secondary to Bartter syndrome was put on recombinant human growth hormone therapy. At follow-ups of the patient; upon routine outpatient clinic measurements performed at 18-year-old yielded K:2.4 mmol/l, Cl: 94 mmol/L and spontaneous blood glucose: 120 mg/dl,
19
Medical Science and Discovery, 2017; 4(2):18-22 the patient underwent 75 g glucose tolerance test. The patient with second hour blood glucose: 138 mg/dl and HgbA1c: 6.4% was diagnosed with impaired fasting glucose.
Case 2:
The second twin was examined for the complaints of vomiting, polyuria, polydipsia, dehydration, weight loss and growth retardation beginning from the birth. Likewise the other twin, this patient was also below the 3rd percentile in height and weight. Laboratory tests revealed K:1.46 mmol/l, Na: 131 mmol/l, Mg: 1.7 mg/dL, Cl: 92 mmol/l and Ca: 9.5 mg/dl, while blood gas showed pH: 7.57, HCO3: 30.2 mmol/l and pCO2: 22.3 mmHg. The patient's Aldesterone was >2000 pg/ml and Angiotensin-1: >9 ng/ml and similarly to the other twin, the patient was diagnosed with Bartter syndrome when he was 11-month-old. Upon the patient developed growth retardation, ordered GH was found as 0.068 ng/ml (0.14-15.7) and IGF-1 as 39.7 ng/ml (288-736). The patient was diagnosed with growth hormone deficiency secondary to Bartter syndrome and recombinant human growth hormone therapy was initiated. Blood tests at routine outpatient examination of the patient carried out at 18-year-old revealed Na: 137 mmol/l, K: 2.4 mmol/l, Cl: 93 mmol/l and spontaneous fasting blood glucose: 165 mg/dl.
Hereupon the patient underwent 75 g OGTT. Upon the second hour blood glucose was 142 mg/dl and Hemoglobin A1c was 6.3%, diagnosis of diabetes mellitus was established.
Case 3:
A 40-year-old female patient was examined upon the routine study revealed Mg:1.2 mg/dll and K: 2.8 mmol/l. Blood gas analysis showed pH: 7.49, pCO2: 38 mmHg, and HCO3: 32 mEq/l in the patient who was then diagnosed with Gitelman syndrome with nephrocalcinosis found on the plain renal radiography ordered and daily urinary calcium below 50 mg/day. In gene analysis, SCL12A3 homozygous gene defect was identified and the patient was taken under followup and treatment. Upon at follow-ups the patient developed polyuria and polydipsia symptoms, her spontaneous blood glucose was measured and found as 140 mg/dl, therefore she underwent oral glucose tolerance test. Upon the second hour blood glucose was above 200 mg/dl and HgbA1c was found as 7.2, the patient was diagnosed with diabetes mellitus. The patient had no familial history. Her body mass index was under 25 kg/m2. She had also no a history of gestational diabetes mellitus. The patient was taken under follow-up and treatment with the diagnosis of diabetes mellitus secondary to Gitelman syndrome. 
Discussion
Studies have shown that chronic hypokalemia leads to disruption in the secretion of growth hormone and insulin. In diseases progressing with hypokalemia such as Bartter syndrome, resistance develops against growth hormone, insulin and IGF-1 hormone at receptor level. Studies performed have demonstrated that in prolonged hypopotassemia IGF-1, insulin and GH cause alterations in the level of mRNA from which they were cloned (11-12-13-14) . In a study conducted on rats, hypopotassemia has been shown to create changes in transcription of the gene coding these hormones and its product mRNA with an unknown mechanism, reducing the number of receptors (12) .
Insulin release occurs as a result of the opening of Ca channel, entering into the cell following the closure of K-ATPase channels and hyperpolarization (16) .
K+ channel which remain open causes the leakage of K+ from inside to outside of the cell and hyperpolarization cannot occur in this case. Chronic hypopotassemia may cause suppression of hyperpolarization by change of the intra-and extracellular electrical gradient. In addition, decreased amount of extracellular K+ may cause a continuous leakage of K+ from inside to outside of the cell. This mechanism may lead to the development of insulin resistance. In a study, 16 patients diagnosed with GS underwent OGTT after a mean follow-up duration of 11 years.
Six of these patients were diagnosed with overt diabetes mellitus, while 2 patients were diagnosed with isolated glucose tolerance and 2 patients with impaired fasting glucose. In the tests performed in our patients; impaired glucose metabolism was identified in both twin patients after a 17-year follow-up, while the other patient with GS was diagnosed with overt diabetes mellitus after a 8-year follow-up and the secondary causes were ruled out (15) .
All these studies indicate that hypopotassemia has a crucial place in growth hormone and insulin hormone cycles. In our case, the levels of IGF-1 and GH were decreased despite treatment continued until 18-yearold in the twin patient with chronic hypokalemia who was diagnosed with Bartter syndrome 11 months after the birth, height and weight were below the 3rd percentile and both twins developed impaired glucose metabolism in the progressing course, supporting these theories.
Although its mechanism of action is yet to be fully understood, chronic hypopotassemia has been shown to disrupt insulin and glucose regulation. In conclusion potassium plays an important role in insulin, IGF-1 and growth hormone cycle. However, it is still not clear the place of potassium in this hormonal cycle mechanism. Further new studies at molecular level are needed in order to clarify this issue.
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